Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by PFG Investments LLC

PFG Investments LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 6.6% in the third quarter, Holdings Channel reports. The institutional investor owned 26,850 shares of the biotechnology company’s stock after selling 1,900 shares during the quarter. PFG Investments LLC’s holdings in Aurinia Pharmaceuticals were worth $197,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AUPH. SG Americas Securities LLC increased its position in shares of Aurinia Pharmaceuticals by 4,307.9% in the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after purchasing an additional 535,301 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in Aurinia Pharmaceuticals in the second quarter worth about $1,713,000. GSA Capital Partners LLP increased its holdings in Aurinia Pharmaceuticals by 196.1% in the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after buying an additional 231,260 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at approximately $1,155,000. Finally, Nordea Investment Management AB lifted its holdings in Aurinia Pharmaceuticals by 51.7% during the 1st quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after buying an additional 105,100 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ AUPH opened at $7.21 on Friday. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.05. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -17.12 and a beta of 1.44. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The stock’s 50 day simple moving average is $7.00 and its 200 day simple moving average is $5.99.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted ($0.08) earnings per share. Equities research analysts expect that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Analyst Ratings Changes

AUPH has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.